Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nature Biotechnology

• Publication date

  2003-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/nbt812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor Activity of Tumor Necrosis Factor a Conjugated with Divinyl Ether and Maleic Anhydride Copolymer on Solid Tumors in Mice'

  2006cited by this paper
• Phase I study of recombinant human tumor necrosis factor

  2004cited by this paper
• Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

  2002cited by this paper
• Sequential Administration of Interferon-&ggr;, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial

  2001cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Structural and Biologic Characterization of Pegylated Recombinant IFN-α2b

  2001cited by this paper
• Population pharmacokinetic analysis of pegylated interferon alfa‐2b and interferon alfa‐2b in patients with chronic hepatitis C

  2001cited by this paper
• Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice

  2000cited by this paper
• Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.

  2000cited by this paper
• Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.

  2000cited by this paper
• Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice.

  2000cited by this paper
• Site-directed polyethylene glycol modification of trichosanthin: effects on its biological activities, pharmacokinetics, and antigenicity.

  1999cited by this paper
• Improving antibody affinity by mimicking somatic hypermutation in vitro

  1999cited by this paper
• PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency

  1997cited by this paper
• Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.

  1997cited by this paper
• Organ targeting In vivo using phage display peptide libraries

  1996cited by this paper
• Selective Enhancement by Tumor Necrosis Factor‐α of Vascular Permeability of New Blood Vessels Induced with Agarose Hydrogel‐entrapped Meth‐A Fibrosarcoma Cells

  1996cited by this paper
• Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.

  1996cited by this paper
• Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

  1995cited by this paper
• Phase I Study of Tumor Necrosis Factor Plus Actinomycin D in Patients with Androgenindependent Prostate Cancer

  1995cited by this paper
• Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.

  1994cited by this paper
• L-asparaginase and PEG asparaginase--past, present, and future.

  1993cited by this paper
• A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cited by this paper
• Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

  1992cited by this paper
• Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis.

  1991cited by this paper
• Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.

  1991cited by this paper
• Mutational analysis of structure--activity relationships in human tumor necrosis factor-alpha.

  1990cited by this paper
• Structure of tumour necrosis factor

  1989cited by this paper
• Antibody-selectable filamentous fd phage vectors: affinity purification of target genes.

  1988cited by this paper
• Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.

  1985cited by this paper
• Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice

  1984cited by this paper
• An endotoxin-induced serum factor that causes necrosis of tumors.

  1975cited by this paper

• An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.

  2024cites this paper
• Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis.

  2024cites this paper
• Advances in Pulmonary Protein Delivery Systems

  2024cites this paper
• Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

  2024cites this paper
• Modified Bacteriophage for Tumor Detection and Targeted Therapy

  2023cites this paper
• Folate Conjugated Polyethylene Glycol Probe for Tumor-Targeted Drug Delivery of 5-Fluorouracil

  2022cites this paper
• Protein Engineering Strategies for Improved Pharmacokinetics

  2021cites this paper
• Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics

  2020cites this paper
• Protein modification by bis-alkylation

  2020cites this paper
• High-resolution purification of a therapeutic PEGylated protein using a cuboid packed-bed device.

  2020cites this paper
• Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.

  2019cites this paper
• Interferons and Interleukins

  2019cites this paper
• Site-selective protein conjugation at histidine

  2018cites this paper
• A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.

  2018cites this paper
• A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification

  2017cites this paper
• An approach for half‐life extension and activity preservation of an anti‐diabetic peptide drug based on genetic fusion with an albumin‐binding aptide

  2017cites this paper
• Conjugates: Biosynthetic-Synthetic Polymer Based

  2017cites this paper
• Protein-Grafted Polymers Prepared Through a Site-Specific Conjugation by Microbial Transglutaminase for an Immunosorbent Assay.

  2017cites this paper
• PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals

  2017cites this paper
• Polymerization of Ethylene Oxide, Propylene Oxide, and Other Alkylene Oxides: Synthesis, Novel Polymer Architectures, and Bioconjugation.

  2016cites this paper
• Development of novel drug delivery systems using phage display technology for clinical application of protein drugs

  2016cites this paper
• PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance

  2016cites this paper
• Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique

  2016cites this paper
• Fusion of an albumin-binding domain extends the half-life of immunotoxins.

  2016cites this paper
• Well-defined biohybrids using reversible-deactivation radical polymerization procedures.

  2015cites this paper
• PEGylated Exendin-4, a Modified GLP-1 Analog Exhibits More Potent Cardioprotection than Its Unmodified Parent Molecule on a Dose to Dose Basis in a Murine Model of Myocardial Infarction

  2015cites this paper
• Protein-polymer therapeutics: a macromolecular perspective.

  2015cites this paper
• Role of polymer–drug conjugates in organ-specific delivery systems

  2015cites this paper
• Two site genetic incorporation of varying length polyethylene glycol into the backbone of one peptide.

  2015cites this paper
• Variants de fc d'igg avec des groupes amine limités qui conservent des propriétés fonctionnelles

  2015cites this paper
• PRINT: A Protein Bioconjugation Method with Exquisite N-terminal Specificity

  2015cites this paper
• Chemoselective Protein Modifications: Methods and Applications for the Functionalization of Viral Capsids

  2015cites this paper
• Structural basis for signal initiation by TNF and TNFR

  2015cites this paper
• Site-specific protein labeling in the pharmaceutical industry: experiences from novartis drug discovery.

  2015cites this paper
• Site-directed modification of genetically engineered Proteus sp. lipase K107 variants with a polyethylene glycol derivative

  2015cites this paper
• Antitumor activity of TNF-α after intratumoral injection using an in situ thermosensitive hydrogel

  2015cites this paper
• Solid-phase polyethylene glycol conjugation using hydrophobic interaction chromatography.

  2014cites this paper
• Next Generation Delivery System for Proteins and Genes of Therapeutic Purpose: Why and How?

  2014cites this paper
• A new reagent for stable thiol-specific conjugation.

  2014cites this paper
• Physico-Chemical and Biochemical Properties of Bioconjugates

  2014cites this paper
• Process for protein PEGylation.

  2014cites this paper
• Multiple amino acid-excluded genetic codes for protein engineering using multiple sets of tRNA variants.

  2014cites this paper
• Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action

  2014cites this paper
• Facile purification of Escherichia coli expressed tag-free recombinant human tumor necrosis factor alpha from supernatant.

  2014cites this paper
• Experimental Evolution of a Green Fluorescent Protein Composed of 19 Unique Amino Acids without Tryptophan

  2014cites this paper
• PEGylation and its impact on the design of new protein-based medicines.

  2014cites this paper
• "Bio"-macromolecules: polymer-protein conjugates as emerging scaffolds for therapeutics.

  2014cites this paper
• Inhaled proteins: challenges and perspectives.

  2013cites this paper
• Generating functional mutant proteins to create highly bioactive anticancer biopharmaceuticals

  2013cites this paper
• The number of amino acids in a genetic code

  2013cites this paper
• Biodegradation of feather keratin with a PEGylated protease of Chryseobacterium gleum

  2013cites this paper
• Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody.

  2013cites this paper
• Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

  2013cites this paper
• Chemical and Genetic Modification

  2013cites this paper
• Enhanced Stability and Antitumoral Activity Single-Chain TNF, a TNF Derivative with

  2013influential citation
• PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update

  2013cites this paper
• Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy.

  2013cites this paper
• Tunable thioesters as "reduction" responsive functionality for traceless reversible protein PEGylation.

  2013cites this paper
• Applications of the In Vitro Virus (IVV) Method for Various Protein Functional Analyses

  2013cites this paper
• Engineering death receptor ligands for cancer therapy.

  2013cites this paper
• Molecular Sieving on the Surface of a Protein Provides Protection Without Loss of Activity

  2013cites this paper
• Novel TNF-α receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice.

  2012cites this paper
• Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.

  2012cites this paper
• Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon.

  2012cites this paper
• Site-Specific PEGylation of Therapeutic Proteins via Optimization of Both Accessible Reactive Amino Acid Residues and PEG Derivatives

  2012cites this paper
• Synthesis of NAC capped near infrared-emitting CdTeS alloyed quantum dots and application for in vivo early tumor imaging.

  2012cites this paper
• Genetic PEGylation

  2012cites this paper
• A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X.

  2012cites this paper
• Orthogonal biofunctionalization of magnetic nanoparticles via ``clickable'' poly(ethylene glycol) silanes: a ``universal ligand'' strategy to design stealth and target-specific nanocarriers

  2012cites this paper
• Simplification of the genetic code: restricted diversity of genetically encoded amino acids

  2012cites this paper
• Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.

  2012cites this paper
• Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL

  2012cites this paper
• Pharmaceutical perspectives for the delivery of TNF-α in cancer therapy

  2012cites this paper
• A Novel Solid-Phase Site-Specific PEGylation Enhances the In Vitro and In Vivo Biostabilty of Recombinant Human Keratinocyte Growth Factor 1

  2012cites this paper
• Preparation of well-defined poly(ether-ester) macromers: photogelation and biodegradability.

  2011cites this paper
• Development of a novel DDS for site-specific PEGylated proteins

  2011cites this paper
• Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma

  2011cites this paper
• Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.

  2011cites this paper
• Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.

  2011cites this paper
• Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.

  2011cites this paper
• Purification of pegylated proteins.

  2011cites this paper
• Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity

  2011influential citation
• Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction.

  2011cites this paper
• Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation.

  2011cites this paper
• Anti-inflammatory effects of a novel TNFR1-selective antagonistic TNF mutant on established murine collagen-induced arthritis.

  2011cites this paper
• High-level production of uricase containing keto functional groups for site-specific PEGylation

  2011cites this paper
• Drug Conjugates with Poly(Ethylene Glycol)

  2011cites this paper
• Development of functional cytokine mutants bymolecular evolution and drug delivery technology

  2011cites this paper
• Applications of Polymer Bioconjugates

  2011cites this paper
• Development of novel PEGylation approaches based on non-covalent interactions

  2011cites this paper
• Solution of the Structure of the TNF-TNFR2 Complex

  2010cites this paper
• Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.

  2010cites this paper
• Improved Antitumor Activity and Tumor Targeting of NH2-Terminal–Specific PEGylated Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand

  2010cites this paper
• Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain*

  2010cites this paper
• Novel Fusion Proteins of Interferon α2b Cause Growth Inhibition and Induce JAK-STAT Signaling in Melanoma

  2010cites this paper
• Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system.

  2010cites this paper
• Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies.

  2010cites this paper
• Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor.

  2010cites this paper
• Delivery of therapeutic proteins.

  2010cites this paper
• Superior serum half life of albumin tagged TNF ligands.

  2010cites this paper